Market Cap 1.49B
Revenue (ttm) 780,000.00
Net Income (ttm) -97.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -12,491.03%
Debt to Equity Ratio 0.00
Volume 276,600
Avg Vol 192,566
Day's Range N/A - N/A
Shares Out 52.38M
Stochastic %K 63%
Beta 0.31
Analysts Strong Sell
Price Target $44.51

Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective a...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 41 711 3960
Website: oculis.com
Address:
Bahnhofstrasse 20, Zug, Switzerland
Champi2305
Champi2305 Jan. 30 at 6:22 PM
$OCS Always Green
0 · Reply
Social_Idiot
Social_Idiot Jan. 28 at 4:10 PM
$OCS beast mode unlocked
0 · Reply
Champi2305
Champi2305 Jan. 28 at 9:55 AM
0 · Reply
Social_Idiot
Social_Idiot Jan. 22 at 11:58 PM
$OCS AI is showing some cooling off. It's a low rated buy. Potentially turning into an exhaustion gap or reversal.
0 · Reply
Social_Idiot
Social_Idiot Jan. 20 at 9:54 PM
$OCS My AI still saying buy.
0 · Reply
Champi2305
Champi2305 Jan. 17 at 11:58 AM
$OCS Volume increasing. 1st target at $28. I keep this stock till $200. A buyout is obvious in the 2 or 3 next years when Oculis will demonstrate the huge potential in MS relapse.
0 · Reply
Social_Idiot
Social_Idiot Jan. 16 at 10:35 PM
$OCS My AI still saying it's a buy.
0 · Reply
Champi2305
Champi2305 Jan. 16 at 8:16 PM
$OCS This is a just the beginning.
0 · Reply
Champi2305
Champi2305 Jan. 16 at 11:46 AM
$OCS https://investors.oculis.com/static-files/f33f41c2-2c60-4985-a6db-c42b1f8fb477
0 · Reply
Champi2305
Champi2305 Jan. 16 at 11:44 AM
$OCS https://www.neurologylive.com/view/neuroprotective-agent-privosegtor-gains-fda-breakthrough-designation-optic-neuritis
0 · Reply
Latest News on OCS
Oculis to Participate in Upcoming November Investor Conferences

Nov 5, 2025, 4:00 AM EST - 3 months ago

Oculis to Participate in Upcoming November Investor Conferences


Oculis to Participate in Upcoming September Investor Conferences

Aug 28, 2025, 4:00 AM EDT - 5 months ago

Oculis to Participate in Upcoming September Investor Conferences


Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D.

Aug 25, 2025, 4:00 AM EDT - 5 months ago

Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D.


Oculis Upsized Loan Facility to Access up to CHF 100 million

Aug 1, 2025, 4:00 AM EDT - 6 months ago

Oculis Upsized Loan Facility to Access up to CHF 100 million


Oculis Publishes Results of 2025 Annual General Meeting

Jun 5, 2025, 4:00 AM EDT - 8 months ago

Oculis Publishes Results of 2025 Annual General Meeting


Oculis to Participate in Upcoming June Investor Conferences

Jun 3, 2025, 4:00 AM EDT - 8 months ago

Oculis to Participate in Upcoming June Investor Conferences


Oculis Publishes Invitation to the Annual General Meeting

May 9, 2025, 4:05 PM EDT - 9 months ago

Oculis Publishes Invitation to the Annual General Meeting


Oculis Reports Q1 Financial Results and Provides Company Update

May 8, 2025, 4:05 PM EDT - 9 months ago

Oculis Reports Q1 Financial Results and Provides Company Update


Oculis to Present at Upcoming May Investor Conferences

May 7, 2025, 4:00 AM EDT - 9 months ago

Oculis to Present at Upcoming May Investor Conferences


Oculis Updates Share Capital

Apr 25, 2025, 4:00 PM EDT - 10 months ago

Oculis Updates Share Capital


Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award

Apr 17, 2025, 5:00 AM EDT - 10 months ago

Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award


Oculis to Present at Upcoming March Investor Conference

Mar 5, 2025, 4:00 AM EST - 11 months ago

Oculis to Present at Upcoming March Investor Conference


Oculis Is An Interesting Growth Bet On Non-Invasive Eye Care

Jan 21, 2025, 8:00 AM EST - 1 year ago

Oculis Is An Interesting Growth Bet On Non-Invasive Eye Care


Oculis to Present at the Stifel 2024 Healthcare Conference

Nov 13, 2024, 4:00 AM EST - 1 year ago

Oculis to Present at the Stifel 2024 Healthcare Conference


Oculis to Present at Upcoming September Investor Conferences

Aug 29, 2024, 4:00 AM EDT - 1 year ago

Oculis to Present at Upcoming September Investor Conferences


Champi2305
Champi2305 Jan. 30 at 6:22 PM
$OCS Always Green
0 · Reply
Social_Idiot
Social_Idiot Jan. 28 at 4:10 PM
$OCS beast mode unlocked
0 · Reply
Champi2305
Champi2305 Jan. 28 at 9:55 AM
0 · Reply
Social_Idiot
Social_Idiot Jan. 22 at 11:58 PM
$OCS AI is showing some cooling off. It's a low rated buy. Potentially turning into an exhaustion gap or reversal.
0 · Reply
Social_Idiot
Social_Idiot Jan. 20 at 9:54 PM
$OCS My AI still saying buy.
0 · Reply
Champi2305
Champi2305 Jan. 17 at 11:58 AM
$OCS Volume increasing. 1st target at $28. I keep this stock till $200. A buyout is obvious in the 2 or 3 next years when Oculis will demonstrate the huge potential in MS relapse.
0 · Reply
Social_Idiot
Social_Idiot Jan. 16 at 10:35 PM
$OCS My AI still saying it's a buy.
0 · Reply
Champi2305
Champi2305 Jan. 16 at 8:16 PM
$OCS This is a just the beginning.
0 · Reply
Champi2305
Champi2305 Jan. 16 at 11:46 AM
$OCS https://investors.oculis.com/static-files/f33f41c2-2c60-4985-a6db-c42b1f8fb477
0 · Reply
Champi2305
Champi2305 Jan. 16 at 11:44 AM
$OCS https://www.neurologylive.com/view/neuroprotective-agent-privosegtor-gains-fda-breakthrough-designation-optic-neuritis
0 · Reply
Champi2305
Champi2305 Jan. 15 at 6:37 PM
$OCUL $OCS will be the next one. amazing pipeline.
0 · Reply
Champi2305
Champi2305 Jan. 14 at 10:18 PM
$OCS great JPM healthcare webconf. Amazing potential. Incredible phases 2 results. Oculis has a ton of cash . Great ceo. Future looks good.
0 · Reply
justiceforb_85
justiceforb_85 Jan. 14 at 7:13 PM
$OCS added. Like the potential on this one, mainly for privosegtor in ON/NAION.
1 · Reply
Champi2305
Champi2305 Jan. 12 at 9:04 PM
$SPY $OCS last call !
0 · Reply
Champi2305
Champi2305 Jan. 9 at 5:33 PM
0 · Reply
TipRanks
TipRanks Jan. 8 at 11:08 AM
J.P. Morgan Bangs the Drum on These 2 ‘Strong Buy’ Stocks https://www.tipranks.com/news/article/j-p-morgan-bangs-the-drum-on-these-2-strong-buy-stocks $OCS $GTX
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Jan. 6 at 4:28 PM
0 · Reply
notreload_ai
notreload_ai Jan. 6 at 3:50 PM
$OCS receives FDA Breakthrough Therapy Designation for Privosegtor, a promising treatment that could become the first neuroprotective therapy for optic neuritis and related eye conditions. https://notreload.xyz/fda-grants-breakthrough-status-to-vision-saving-drug-for-optic-neuritis/
0 · Reply
topstockalerts
topstockalerts Jan. 6 at 2:49 PM
$OCS there it goes…
0 · Reply
IN0V8
IN0V8 Jan. 6 at 2:24 PM
0 · Reply
DonCorleone77
DonCorleone77 Jan. 6 at 2:08 PM
$OCS $ZETA $AEVA $MCHP $ALMS PRE-MARKET MOVERS: Currently Higher: - Alumis (ALMS) up 133.4% after psoriasis trial hits endpoints - Aeva (AEVA) up 26.7% after announcing 4D LiDAR integration within Nvidia (NVDA) Drive Hyperion - OneStream (OS) up 27.4% after Bloomberg reported Hg is in advanced talks to acquire the company - Oculis (OCS) up 11.3% after Privosegtor was granted breakthrough therapy designation by the FDA - Zeta Global (ZETA) up 9.0% after announcing a strategic collaboration with OpenAI - Microchip (MCHP) up 4.4% after raising its Q3 revenue guidance - Vistra (VST) up 3.7% after agreeing to acquire Cogentrix Energy for $4B Currently Lower: - Madrigal Pharmaceuticals (MDGL) down 2.1% after Wolfe Research downgraded the stock to Peer Perform and removed the firm's prior $579 price target - Weave (WEAV) down 1.3% after Raymond James downgraded shares to Outperform from Strong Buy with a price target of $10, down from $12 - Lennar (LEN) down 0.9% after UBS downgraded the stock to Neutral with a price target of $122, down from $137 - D.R. Horton (DHI) down 1.7% after Wells Fargo downgraded shares to Equal Weight with a price target of $155, down from $180
0 · Reply
OpenOutcrier
OpenOutcrier Jan. 6 at 1:55 PM
$OCS (+11.3% pre) Oculis stock surges after FDA grants breakthrough therapy designation https://ooc.bz/l/88727
0 · Reply